Recently, one of the biggest biotech dividend stocks, PDL BioPharma (Nasdaq: PDLI), announced that its CFO has left the company for "personal reasons." While investors are always wary of management shakeups, this move had little effect on the company's share price.

In the following video, health-care analysts Max Macaluso and Brenton Flynn discuss this move and one issue PDL BioPharma investors must continue to keep a close eye on.